Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jan;38(1):68-77.
doi: 10.5534/wjmh.180052M. Epub 2018 Sep 12.

Long-Term Testosterone Therapy in Type 2 Diabetes Is Associated with Decreasing Waist Circumference and Improving Erectile Function

Geoffrey Hackett  1   2 , Nigel Cole  1 , Akhilesh Mulay  3 , Richard C Strange  4 , Sudarshan Ramachandran  5   6   7
Affiliations

Long-Term Testosterone Therapy in Type 2 Diabetes Is Associated with Decreasing Waist Circumference and Improving Erectile Function

Geoffrey Hackett et al. World J Mens Health. 2020 Jan.

Abstract

Purpose: To describe the 4-year metabolic follow-up results from the BLAST study.

Materials and methods: Baseline hemoglobin A1c (HbA1c), weight, and waist circumference (WC) data were recorded in 185 men recruited for the BLAST randomised controlled trial (RCT) and erectile function (EF) scores were also available in an additional 48 men screened for the RCT. Intra/inter-group associations between these parameters and testosterone replacement therapy (TRT) were assessed at 1) end of the RCT (30 weeks), 2) open-label phase (82 weeks), and 3) final assessment via non-parametric statistics.

Results: Improvement in HbA1c and weight at the end of the RCT and open-label phase in men on TRT was not maintained long-term. The convergence in HbA1c could have been due to incentivised care with HbA1c targets. Interestingly those on TRT at final assessment required fewer anti-diabetic agents. The weight increase in routine care may have been due to changes in diabetes medication or an increase in lean muscle mass. WC continued to decrease in men on TRT indicating possible reduction in visceral fat. Improvement in EF scores continued with long-term TRT, this was abolished when TRT was discontinued.

Conclusions: This study hints at benefits in glycaemic control, weight and WC, and long-term RCTs studying mechanisms of benefit and clinical outcomes are necessary. Our results also show that EF scores continued to improve with long-term TRT, even beyond the 6 months that we previously reported in the BLAST RCT.

Keywords: Diabetes mellitus, type 2; Erectile dysfunction; Hypogonadism; Testosterone.

PubMed Disclaimer

Conflict of interest statement

Professor Geoffrey Hackett has received honoraria for acting as a speaker for Bayer plc who provided the grant. Professor Sudarshan Ramachandran has received educational grants to attend meetings and honoraria for serving as a speaker for Besins Health Care Ltd. Professor Geoffrey Hackett has spoken at various national and international meetings on testosterone and PDE5I treatments in men. These companies and activities had no influence on this project. And other authors have no potential conflicts of interest to disclose.

Figures

Fig. 1
Fig. 1. Patient recruitment for the BLAST randomised controlled trial (RCT). Of the 857 men screened 199 men took part in the BLAST RCT evaluating changes in metabolic parameters and sexual function scores after 30 weeks of testosterone replacement therapy compared with placebo. IIEF: international index of erectile function, TT: total testosterone, SHBG: sex hormone-binding globulin, HbA1c: hemoglobin A1c, PSA: prostate specific antigen, T2DM: type 2 diabetes, FT: free testosterone, TU: testosterone undecanoate, P: placebo, T: testosterone.
Fig. 2
Fig. 2. Changes in hemoglobin A1c (HbA1c) (low testosterone [low T]/treated and low T/untreated men) during the 30-week BLAST randomised controlled trial, open-label (30–82 weeks), and normal care (post 82 weeks) phases. The low T/treated group were further stratified into low T/treated/stopped and low T/treated/continuous groups depending on whether testosterone replacement therapy was continued or not. The number of drugs prescribed to control diabetes in each group is also shown. SE: standard error.
Fig. 3
Fig. 3. Change in weight (low testosterone [low T]/treated and low T/untreated men) during the 30-week BLAST randomised controlled trial, open-label (30–82 weeks), and normal care (post 82 weeks) phases. The low T/treated group were further stratified into low T/treated/stopped and low T/treated/continuous groups depending on whether testosterone replacement therapy was continued or not. SE: standard error.
Fig. 4
Fig. 4. Change in waist circumference (WC) (low testosterone [low T]/treated and low T/untreated men) during the 30-week BLAST randomised controlled trial, open-label (30–82 weeks), and normal care (post 82 weeks) phases. The low T/treated group were further stratified into low T/treated/stopped and low T/treated/continuous groups depending on whether testosterone replacement therapy was continued or not. SE: standard error.
Fig. 5
Fig. 5. Changes in international index of erectile function (IIEF) erectile function (EF) (low testosterone [low T]/treated and low T/untreated men) during the 30 week BLAST randomised controlled trial (RCT), open-label (30–82 weeks), and normal care (post 82 weeks) phases in men recruited to the BLAST RCT and those screened with baseline IIEF EF scores. The low T/treated group were further stratified into low T/treated/stopped and low T/treated/continuous groups. SE: standard error.
See this image and copyright information in PMC

References

    1. Hackett G, Cole N, Deshpande A, Popple M, Kennedy D, Wilkinson P. Biochemical hypodonadism and type 2 diabetes in primary care. Br J Diab Vasc Dis. 2009;9:226–231.
    1. Saad F, Haider A, Doros G, Traish A. Long-term treatment of hypogonadal men with testosterone produces substantial and sustained weight loss. Obesity (Silver Spring) 2013;21:1975–1981. - PubMed
    1. Traish AM, Haider A, Doros G, Saad F. Long-term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome: an observational, long-term registry study. Int J Clin Pract. 2014;68:314–329. - PMC - PubMed
    1. Hackett G, Cole N, Bhartia M, Kennedy D, Raju J, Wilkinson P, et al. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study) Int J Clin Pract. 2014;68:203–215. - PubMed
    1. Hackett G, Cole N, Bhartia M, Kennedy D, Raju J, Wilkinson P. Testosterone replacement therapy improves metabolic parameters in hypogonadal men with type 2 diabetes but not in men with coexisting depression: the BLAST study. J Sex Med. 2014;11:840–856. - PubMed

Grants and funding